We report that the bone marrow (BM) stroma-released LL-37, a member of the cathelicidin family of antimicrobial peptides, primes/increases the responsiveness of murine and human hematopoietic stem/progenitor cells (HSPCs) to an a-chemokine stromal-derived factor-1 (SDF-1) gradient. Accordingly, LL-37 is upregulated in irradiated BM cells and enhances the chemotactic responsiveness of hematopoietic progenitors from all lineages to a low physiological SDF-1 gradient as well as increasing their (i) adhesiveness, (ii) SDF-1-mediated actin polymerization and (iii) MAPK p42/44 phosphorylation. Mice transplanted with BM cells ex vivo primed by LL-37 showed accelerated recovery of platelet and neutrophil counts by B3-5 days compared with mice transplanted with unprimed control cells. These priming effects were not mediated by LL-37 binding to its receptor and depended instead on the incorporation of the CXCR4 receptor into membrane lipid rafts. We propose that LL-37, which has primarily antimicrobial functions and is harmless to mammalian cells, could be clinically applied to accelerate engraftment as an ex vivo priming agent for transplanted human HSPCs. This novel approach would be particularly important in cord blood transplantations, where the number of HSCs available is usually limited.
Introduction
Current strategies to accelerate hematopoietic reconstitution after transplantation include transplantation of greater numbers of hematopoietic stem/progenitor cells (HSPCs) or ex vivo expansion of harvested HSPCs before transplantation. However, in clinical settings, the number of HSPCs available for allogeneic or autologous transplantation can be low (for example, umbilical cord blood (UCB) or in individuals who are poor mobilizers) and strategies to expand HSCs and maintain equivalent engraftment capability ex vivo are limited. 1 We have reported that some compounds present in leukapheresis products, such as platelet-derived microparticles 2 and the complement cascade cleavage fragment anaphylatoxin C3a, 3 enhance the homing responses of HSPCs to a low stromal-derived factor-1 (SDF-1) gradient. Similar effects have been described by other investigators for hyaluronic acid, 4 the sphingosine-1-phosphate receptor agonist FTY20, 5 UTP 6 and prostaglandin-E2 (PGE2). 7 Collectively, these results demonstrate that the homing responses of HSPCs can be positively modulated by several factors related to inflammation or tissue injury.
In our previous work, we demonstrated that conditioned media harvested from granulocytes activated with the fifth complement cascade protein (C5) cleavage fragment, C5a anaphylatoxin, also enhance the responsiveness of HSPCs to an SDF-1 gradient. 8 Therefore, we became interested in identifying which factors released from C5a-stimulated granulocytes are responsible for this effect and focused on the cationic peptide LL-37, a member of the cathelicidin family. 8 Interestingly, LL-37, like anaphylatoxin C3a, which we previously identified, belongs to a group of antimicrobial cationic peptides (AMPs). 3, 9 AMPs are host-defense peptides and are an evolutionarily conserved component of the innate immune response that, as previously demonstrated, destroy bacteria, enveloped viruses, fungi and even transformed cancerous cells, but do not affect the viability of normal eukaryotic cells. These selective effects of AMPs in destroying bacteria, but not normal eukaryotic cells, depend on differences in electrostatic and hydrophobic properties of cell membranes between prokaryotic and eukaryotic cells.
We have reported that LL-37, like C3a, enhances the chemotactic responsiveness of colony-forming units of granulocytes/macrophages (CFU-GM) to a low SDF-1 gradient. 8 This effect, like that described for C3a, is dependent on the incorporation of the SDF-1 receptor CXCR4 into membrane lipid rafts. At the mechanistic level, CXCR4 exerts stronger signaling and more robust responsiveness to low doses of SDF-1 after inclusion into lipid rafts. 3 The aim of this report is to shed more light on this LL-37 priming phenomenon by using appropriate in vitro and in vivo models. First, we provide evidence that LL-37 is upregulated in the bone marrow (BM) after irradiation and selectively primes the responsiveness of HSPCs from all hematopoietic lineages to SDF-1, but not to other newly identified homing factors, such as sphingosine-1-phosphate or ceramide-1-phosphate. 10, 11 Second, we observed that LL-37 enhances the migration of HSPCs even at a very low level of SDF-1 (1-2 ng/ml), which supports the notion that the phenomenon of priming modulates the responsiveness of HSPCs to physiological concentrations of SDF-1 in tissues without the necessity of increasing SDF-1 secretion. Third, LL-37 enhances the adhesiveness of hematopoietic progenitors, activates MAPK p42/44 in these cells and induces actin polymerization. Finally, syngeneic BM cells exposed for 30 min ex vivo to LL-37 and subsequently transplanted into lethally irradiated recipients accelerated the recovery of platelets and neutrophils by B3-5 days in transplanted animals as compared with mice transplanted with unprimed control BM cells.
Based on the foregoing, we envision that LL-37, which has primarily antimicrobial functions and is harmless to mammalian cells, could be clinically applied to prime ex vivo human HSPCs before transplantation. This novel approach would be particularly important in UCB transplantation, where the number of HSPCs available for transplantation is usually limited.
Materials and methods

Animals
Pathogen-free, 4-to 6-week-old C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD, USA). Mice were allowed to adapt for at least 2 weeks and used for experiments at age 6-8 weeks. The animal studies were approved by the Animal Care and Use Committee of the University of Louisville (Louisville, KY, USA).
BM nucleated cells
BM nucleated cells (BMNCs) were isolated by flushing the femurs and tibias of pathogen-free C57BL/6 mice. Whole-BM cells were suspended in BD Pharm Lyse buffer (BD Biosciences, San Jose, CA, USA) to remove RBCs, washed and resuspended in RPMI medium (Thermo Fisher Scientific, South Logan, UT, USA) containing 0.5% bovine serum albumin (Sigma-Aldrich, St Louis, MO, USA).
Human UCB cells
Cord blood cells were obtained from healthy volunteer donors who had given informed consent and the protocols used were approved by the institutional review board of the University of Louisville. Cord blood nucleated cells were isolated by lysis of RBCs, as described above.
Chemotaxis and colony-forming assays
Medium (650 ml/well) containing resuspension medium, rhSDF-1, LL-37 (AnaSpec, Fremont, CA, USA) and the WKYMVM peptide (Tocris Bioscience, Ellisville, MI, USA) was added to the lower chambers of a Costar Transwell with 5-mm-filter, 24-well plates (Costar Corning, Cambridge, MA, USA). A cell suspension (1 Â 10 6 cells/100 ml) was loaded into the upper chambers, the cultures were incubated (37 1C, 95% humidity and 5% CO 2 ) for 3 h and subsequently cells in the lower chambers were harvested and counted by fluorescence-activated cell sorting. Migrated cells were assayed for the number of CFU-GM. Briefly, cells were resuspended in human methylcellulose base medium (R&D Systems, Minneapolis, MN, USA) and supplemented with granulocyte-macrophage colony-stimulating factor (25 ng/ml) and interleukin-3 (10 ng/ml) for CFU-GM; with granulocyte colony-stimulating factor (20 ng/ml) for CFU-granulocyte; with macrophage colony-stimulating factor (10 ng/ml) for CFUmacrophage; with erythropoietin (5 U/ml; Stem Cell Tech., Vancouver, BC, Canada) and stem cell factor (5 ng/ml) for burst forming units of erythrocytes and with thrombopoietin (100 ng/ ml) for CFU-megakaryocyte. Cultures were incubated for 6-10 days and scored under an inverted microscope. CFU-GM, CFUgranulocyte, CFU-macrophage, CFU-megakaryocyte and burst forming units of erythrocytes of cord blood cells were cultured as described previously. 3 For toxicity assay, 1-12.5 mg/ml LL-37 was added to the culture systems. In some experiments, to evaluate the influence of lipid raft formation on cell migration, cells were pre-incubated with 2.5 mM methyl-b-cyclodextran (MbCD; Sigma-Aldrich).
BM transplantation
Female 6-to 8-week-old C57BL/6 mice were irradiated with a lethal dose of g-irradiation (950 cGy). Twenty-four hours after irradiation, mice were transplanted with 5 Â 10 5 murine bone marrow mononuclear cells by tail vein injection. Murine bone marrow mononuclear cells were either pretreated with 2.5 mg/ml LL-37 or medium for 30 min at 37 1C, 95% humidity and 5% CO 2 . Transplanted mice were bled at various intervals (0, 5, 7, 11, 16 and 21 days after transplantation) from the retro-orbital plexus using sterilized Pasteur pipettes (Fisher Scientific, Pittsburgh, PA, USA) and Microvette EDTA-coated tubes (Sarstedt Inc., Newton, NC, USA). The WBC and platelet count were analyzed by Hemavet 950 (Drew Scientific Inc., Oxford, CT, USA). For the CFU-spleen assay, spleens were isolated 12 days after transplantation, fixed in Telesyniczky's solution and CFU-spleen colonies were counted on the spleen surface. For the CFU-GM assay, femoral BMNCs were isolated 16 days after transplantation and cultured for CFU-GM, as described above.
Sorting of BMNCs
Lin À Sca-1 þ CD45 þ cells and Sca-1 þ cells were purified as described elsewhere. Briefly, BMNCs were resuspended in RPMI medium containing 2% fetal bovine serum and incubated for 30 min on ice with the following antibodies: biotinconjugated rat anti-mouse Ly-6A/E (Sca-1, clone E13-161.7), streptavidin-phycoerythrin (PE)-Cy5 conjugate, anti-CD45-APC-Cy7 (clone 30-F11), anti-CD45R/B220-PE (clone RA3-6B2), anti-Gr-1-PE (clone RB6-8C5), anti-TCRa/b-PE (clone H57-597), anti-TCRg/z-PE (clone GL3), anti-CD11b-PE (clone M1/70) and anti-Ter-119-PE (clone TER-119). All antibodies were purchased from BD Biosciences and were added at saturating concentrations. Cells were then washed twice and resuspended in RPMI medium containing 2% fetal bovine serum and sorted by multi-parameter, live sterile cell sorting (MoFlo; Dako A/S, Fort Collins, CO, USA).
Phosphorylation of intracellular pathway proteins
Cells were kept in RPMI containing 0.5% bovine serum albumin overnight in an incubator to achieve quiescence, stimulated with SDF-1 and/or LL-37 for 2 or 5 min at 37 1C, and then lysed for 30 min on ice with M-per lysing buffer (Pierce, Rockford, IL, USA) containing protease and phosphatase inhibitors (Sigma-Aldrich). The concentrations of extracted proteins were measured with the BCA Protein Assay Kit, according to the manufacturer's instructions (Thermo Scientific, Rockford, IL, USA), and equal amounts of protein were separated and analyzed for phosphorylation of MAPK p44/42 and AKT (Ser473). Equal loading in the lanes was evaluated by stripping the blots and re-probing with antibodies against MAPK p44/42 and AKT. All phosphospecific antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). The membranes were developed with Amersham ECL Western Blotting Detection Reagents and exposed to an Amersham Hyperfilm (GE Healthcare, Chalfont St Giles, UK).
Lipid raft isolation
Lipid rafts were isolated as described previously. 12 Briefly, cells (5 Â 10 7 ) from the human acute monocytic leukemia cell line THP-1 were incubated with or without LL-37 for 30 min in an incubator. MbCD was applied in some experiments to interrupt the formation of lipid rafts. The cells were spun down and lysed in 600 ml of MEB buffer (20 mM MES, 150 mM NaCl, 1 mM EDTA, pH 6.5), containing 1% Triton X-100, protease inhibitor cocktail, phenylmethylsulfonyl fluoride and sodium orthovanadate (Santa Cruz Biotechnology, Santa Cruz, CA, USA), for 1 h on ice. An equal volume of 80% sucrose (w/v, in MEB buffer) was mixed with the cell lysate and placed at the bottom of a 5-ml centrifuge tube (Beckman Coulter Inc., Brea, CA, USA) and overlaid with 30% sucrose and 5% sucrose. Samples were centrifuged at 200 000 g for 17 h at 4 1C with an SW41 rotor (Beckman Coulter Inc.). Fractions were gently removed from the top of the gradient and n-octylglucoside (Sigma-Aldrich) was added to each fraction (100 mM final) to solubilize rafts. An equal volume from each fraction was used for a standard western blot using an anti-CXCR4 antibody (Serotec, Oxford, UK) and an anti-Lyn antibody (Santa Cruz Biotechnology).
Confocal microscopy assay
To visualize lipid rafts, confocal microscopy assay was performed as described previously. 13 Briefly, pre-plated THP-1 cells were incubated with or without LL-37 for 30 min, then washed and fixed in 3.7% paraformaldehyde. Cholera toxin-B subunit conjugated with fluorescein isothiocyanate (Sigma-Aldrich) was applied to detect the ganglioside GM1 and the mouse monoclonal anti-hCXCR4 IgG antibody (R&D Systems), and an Alexa Fluor-568 goat anti-mouse IgG antibody (Invitrogen, Carlsbad, CA, USA) was applied to detect CXCR4. Stained cells were examined and images were generated by using a FLUOVIEW FV1000 laser-scanning confocal microscope (Olympus America Inc., Center Valley, PA, USA).
Actin polymerization
Actin polymerization was determined as described previously. 14 Briefly, cells were resuspended in RPMI containing 0.5% bovine serum albumin at a concentration of 1 Â 10 6 cells/ml and incubated with SDF-1 and/or LL37, and then fixed and permeablized. Alexa-488 phalloidin (Invitrogen) was added to visualize F-actin. The mean fluorescence intensity was measured with an LSR II flow cytometer (Becton Dickinson, Mountain View, CA, USA). The relative fluorescence change was normalized by the change for unstimulated cells.
mRNA quantification for cathelicidin
Total RNA was isolated from cells by using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA, USA). mRNA was reverse transcribed with 500 U of Moloney murine leukemia virus reverse transcriptase primed with oligo-dT, and the resulting cDNA fragments were amplified by using the SYBR Green system (Applied Biosystems, Carlsbad, CA, USA). The primer sequences for b-2 microglobulin were 5 0 -CATACGCCTGCAGAGTTAAG C-3 0 (F) and 5 0 -GATCACATGTCTCGATCCCAGTAG-3 0 (R). For cathelicidin, the primer sequences were 5 0 -CACAGCCC TTTCGGTTCAAG-3 0 (F) and 5 0 -CAATCTTCTCCCCACCTTTG C-3 0 (R). The relative quantity of the target was normalized to an endogenous gene (b-2 microglobulin) and, relative to a calibrator, is calculated as 2 ÀDDC t (fold difference).
Detection of the LL-37 receptor formyl peptide receptor like-1 (FPRL-1) by reverse transcription-PCR Total RNA from BMNCs and purified HSPCs was isolated and reverse transcribed as described above. The resulting cDNA fragments were amplified by sing 5 U of Thermus aquaticus (Taq) polymerase. For FPRL-1 the primer sequences were 5 0 -T CATTGCCTTGGACCGCTGTAT (F) and 5 0 -AAAAGGGGC AAAGTGAGAATGAGAG-3 0 (R). The PCR products were run in 2% agarose gels and photographed under UV light. The sizes of the PCR products were verified against a 100-bp DNA ladder.
Statistical analysis
Arithmetic means and standard deviations were calculated by using the Instat 1.14 software (GraphPad, San Diego, CA, USA). Statistical significance was defined as Po0.05. Data were analyzed by Student's t-test for unpaired samples and t-test for paired samples.
Results
LL-37 is upregulated in irradiated BM and increases the chemotactic responsiveness of progenitor cells from all hematopoietic lineages to a physiological low SDF-1 gradient
Our recent studies identified activated granulocyte-derived LL-37 as a novel SDF-1-CXCR4 axis-priming factor for HSPCs. 8 As in addition to granulocytes, LL-37 has been reported to be secreted from several other cell types, including BM-stroma cells, 9, 15 we evaluated the expression of LL-37 in BM cells isolated from control mice and mice conditioned for transplantation by total-body irradiation (1000 cGy). Figure 1a shows that LL-37 mRNA significantly increases in BM cells isolated from the bones of irradiated mice.
In our previous report, we demonstrated that LL-37 enhances the responsiveness of murine CFU-GM to a low SDF-1 gradient that we arbitrary set as 30 ng/ml. 3, 8 This dose, however, as we recently noticed, is B10 Â higher than physiological tissue concentration of SDF-1. 10 More importantly, as we demonstrate in the current study (Figure 1a ), LL-37 increases the chemotactic responsiveness of clonogenic progenitors to much lower doses of SDF-1 (1-3 ng/ml) that are within the physiological concentration range of SDF-1 in peripheral blood. Interestingly, we have also learned that the LL-37-mediated priming effect is much stronger than that previously described for the C3a LL-37 and stem cell homing W Wu et al anaphylatoxin (data not shown). Furthermore, in the current study we demonstrate that LL-37 exerts its priming effect not only for CFU-GM, as reported previously, 8 but also for all major hematopoietic lineages and has been effective against both murine BM (Figure 1b ) and human umbilical cord blood (UCB) cells (Figure 1c ).
Next, we tested the influence of LL-37 on the activation of pathways related to cell migration in BMNCs. Our signaling studies performed on Sca-1 þ cells sorted by fluorescenceactivated cell sorting (Figure 2a ) revealed that, although LL-37 on its own did not affect the phosphorylation of MAPK p42/44 and AKT, it increased the SDF-1-mediated phosphorylation of MAPK p42/44 LL-37 and stem cell homing W Wu et al ( Figure 2b ) and actin polymerization (Figure 2c ). To our surprise, however, we did not observe any effect of LL-37 on the SDF-1mediated increase in the expression and secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 enzymes, which are involved in the homing of HSPCs by fluorescenceactivated cell sorting-purified Sca-1 þ cells (data not shown).
The priming effect of LL-37 is not mediated by known cell-surface receptors and depends on lipid raft formation
It is known that LL-37 binds to the FPRL-1. 16 Figure 3a shows that Sca-1 þ Lin À CD45 þ cells sorted by fluorescence-activated cell sorting that are highly enriched in HSPCs express the mRNA for this receptor (Figures 3a and b) . Therefore, to address whether FPRL-1 is involved in the priming of HSPCs by LL-37, we used the FPRL-1 receptor ligand 16 WKYMVM and evaluated whether this peptide shows a similar priming effect as LL-37. As shown in Figure 3c , WKYMVM, in contrast to LL-37, was not able to prime the response of clonogeneic progenitors to SDF-1. This suggests that the LL-37-mediated priming effect is FPRL-1independent.
Next, we used several complementary experimental strategies to confirm that the LL-37-mediated priming effect depends on the incorporation of CXCR4 into lipid rafts. First, as membrane cholesterol is crucial for lipid raft formation, cells were depleted of cholesterol before chemotaxis assay by pre-incubating them with MbCD. Figure 4a shows that the SDF-1-CXCR4 axispriming effect was abrogated after the depletion of membrane cholesterol by MbCD. Next, we isolated 11 membrane fractions more or less enriched in lipid rafts from hematopoietic cells (i) stimulated with LL-37, (ii) stimulated with LL-37 after previous depletion of cholesterol by MbCD and (iii) unprimed as control. The expression of CXCR4 in these membrane fraction extracts was evaluated by western blotting (Figure 4b, upper panel) . To visualize lipid rafts, we also used western blot analysis for Lyn expression, which is an established marker for lipid rafts 14 (Figure 4b, lower panel) . Our data show that in cells stimulated by LL-37, CXCR4 was detectable in lipid raft-enriched membrane fractions (fractions 3-4; Figure 4b ). Finally, we evaluated lipid raft formation in hematopoietic cells exposed or not exposed to LL-37 by using confocal microscope analysis (Figure 4c ). Direct confocal analysis revealed colocalization of the CXCR4 receptor with the GM-1 protein, which is another marker of lipid rafts, 12 in cells exposed to LL-37.
Short-term ex vivo pre-incubation of BM cells before transplantation with LL-37 enhances and accelerates the engraftment of HSPCs in vivo
To evaluate whether the AMP LL-37 could be used for ex vivo priming before transplantation of HSPCs, we evaluated its potential toxicity in clonogenic assays, and as expected no effect was observed for either murine or human progenitor cells from all the major hematopoietic lineages (data not shown).
Encouraged by this result, we performed transplantation experiments in vivo. Syngeneic BM cells were exposed or not exposed ex vivo for 30 min to LL-37 and subsequently transplanted into lethally irradiated recipients. We observed that mice transplanted with LL-37-primed cells had, by day 11 after transplantation, a higher number of clonogenic progenitors in long bones (Figure 5a ) and transplanted LL-37-primed cells formed more spleen colonies in the CFU-spleen assay (Figure 5b) .
Finally, syngeneic BM cells were exposed ex vivo for 30 min to LL-37, transplanted into lethally irradiated recipients and the kinetics of the recovery of peripheral blood parameters was measured. We observed an accelerated recovery of platelets and neutrophils of B3-5 days in animals transplanted with primed cells as compared with animals transplanted with unprimed control cells (Figure 5c ).
The priming effect of LL-37 is specific for the SDF-1-CXCR axis
Recently we described an important role for certain bioactive lipids, sphingosine-1-phosphate and ceramide-1-phospate, in the homing of HSPCs to BM. 10, 11 We therefore became interested in whether LL-37 also enhances the responsiveness Figure 4 The priming effect of LL-37 is dependent on enhanced incorporation of CXCR4 into lipid rafts. (a) The LL-37-mediated enhancement of migration of murine CFU-GM in response to an SDF-1 gradient was significantly inhibited by 1-h pretreatment of cells with MbCD (2.5 mM). The values are the percentage increase in the number of migrated cells as compared with the number of migrated cells in response to SDF-1 alone. SDF-1 was used at a dose of 50 ng/ml and LL-37 at a dose of 2.5 mg/ml. The data represent the combined results from three independent experiments performed in duplicate per group (n ¼ 6). *Po0.01. (b) Western blot analysis of the localization of CXCR4 and lipid rafts in different fractions of cell membrane lipids. Membranes were enriched in lipid rafts (fractions 3-4) or depleted of lipid rafts (fractions [10] [11] . The human monocytic cell line, THP-1, pretreated with or without MbCD (2.5 mM), was stimulated with or without LL-37 (2.5 mg/ml). CXCR4 was detected in membrane fractions by western blotting along with Lyn, a marker of lipid rafts. Representative results are shown from three independent experiments. (c) Confocal microscopy analysis of the localization of CXCR4 in lipid rafts. THP-1 cells were cultured for 6 h in serum-free medium and then stimulated without (control) or with LL-37 (2.5 mg/ml). Lipid rafts were stained with cholera toxin-B subunit conjugated with fluorescein isothiocyanate (green) and CXCR4 was stained with the mouse monoclonal anti-hCXCR4 IgG and Alexa Fluor-568 goat anti-mouse IgG (red) antibodies. Stained cells were examined and images were generated by using a FLUOVIEW FV1000 laser-scanning confocal microscope. The white areas indicate colocalization of lipid rafts with CXCR4. The experiment was repeated three times on different cell preparations and a representative image is shown. The color reproduction of this figure is available at the Leukemia journal online. LL-37 and stem cell homing W Wu et al of HSPCs to these other homing factors and observed that the effect of LL-37 is highly SDF-1-specific (Figures 6a and b) .
Next, we wanted to learn whether the priming effect of LL-37 is involved in the chemotactic responsiveness of hematopoietic cells to other chemokines. As HSPCs do not respond to other chemokines except SDF-1 [17] [18] [19] we used the THP-1 cell line as a model system. THP-1 cells, in addition to SDF-1, show chemotaxis in response to macrophage inflammatory protein-1b, monocyte chemotactic protein-1 and interleukin-8. We observed that LL-37 enhances the chemotactic responsiveness of THP-1 cells to SDF-1 only (data not shown), which again suggests the high specificity of LL-37 priming for the SDF-1-CXCR4 axis.
Discussion
The SDF-1-CXCR4 receptor axis has an important role in the retention of HSPCs in the BM. Whereas HSPCs express CXCR4, SDF-1 is expressed by cells in the BM microenvironment (for example, osteoblasts and fibroblasts). It is also well known that SDF-1, when used at supra-physiological concentrations, is a potent in vitro chemoattractant for HSPCs. However, by contrast, the SDF-1 concentration in biological fluids is relatively low (for example, B1-2 ng/ml in peripheral blood). 10 Moreover, we have recently demonstrated that myeloablative conditioning for hematopoietic transplantation induces a highly proteolytic microenvironment in the BM, and, as SDF-1 is extremely sensitive to degradation by proteolytic enzymes, it is rapidly degraded under these conditions. 3, 11, 18, 20 The relatively low physiological concentration of SDF-1 in tissues and its sensitivity to proteolytic enzymes together suggest that some other mechanisms may have an important role in sensitizing the responsiveness of cells to this chemokine.
To support this notion, it has been reported by us and other investigators that platelet-derived microparticles, 2 the LL-37 and stem cell homing W Wu et al complement cascade cleavage fragment anaphylatoxin C3a, 3 hyaluronic acid, 4 the sphingosine-1-phosphate receptor agonist FTY20, 5 UTP 6 and PGE2 7 enhance the responsiveness of HSPCs to an SDF-1 gradient. Thus, these observations collectively suggest that the SDF-1-mediated homing responsiveness of HSPCs is positively modulated by several factors related to inflammation or tissue injury. In this report, we demonstrate that the cationic peptide LL-37 also strongly enhances the responsiveness of HSPCs to an SDF-1 gradient. This priming effect is not receptor-mediated as, as shown here, the LL-37 receptor FPRL-1, 16 as reported previously for receptors for other AMPs (C3a and desArg C3a), 21, 22 is not involved in this process. The molecular mechanism behind this phenomenon is the ability of LL-37, like another cationic peptide anaphylatoxin C3a, to increase the incorporation of CXCR4 into lipid rafts. 8 We envision that cationic AMPs, which as part of innate immunity may destroy bacterial walls, are harmless to eukaryotic cells, which have a different membrane lipid composition, and after exposure perturb only the organization of membrane lipids by non-receptor-mediated mechanisms that promote the formation of lipid rafts. Based on this, the CXCR4 receptor, when incorporated into lipid rafts, better engages downstream signaling molecules, showing an increase in SDF-1-mediated MAPK p42/44 phosphorylation in the presence of LL-37, as demonstrated in this paper.
Interestingly, as the overall level of SDF-1 in the BM after conditioning for transplantation decreases because of induction of a proteolytic environment, 10,11 LL-37 secreted by irradiated BM stroma may enhance by a priming effect the responsiveness of HSPCs to a decreasing SDF-1 gradient in the BM. More importantly, as we demonstrate here for the first time, the strong priming effect of LL-37 is robust in the presence of very low but physiologically relevant doses of SDF-1 (1-3 ng/ml). Therefore, this phenomenon significantly potentiates the biological activity of this chemokine in the BM. Overall, we hypothesize that several factors induced in irradiated BM during conditioning for transplantation, such as LL-37, C3a anaphylatoxin, PGE2 and UTP, may cooperatively enhance the SDF-1-dependent homing gradient for HSPCs. It is an important mechanism to increase responsiveness to low SDF-1 levels, which additionally decreases after myeloablative conditioning for transplantation. 1 However, while we recently proposed that, in addition to SDF-1, certain bioactive lipids, such as sphingosine-1phosphate and ceramide-1-phosphate, also have an important role in homing of HSPCs after transplantation, 11 our results indicate that the effect of LL-37 is specific for the SDF-1-CXCR4 axis only. Furthermore, studies of the THP-1 cell line revealed that, in addition to normal HSPCs, LL-37 may also enhance the responsiveness of malignant cells to an SDF-1 gradient. Again, this effect was specific for SDF-1 and not other chemokine gradients. Based on this finding, the LL-37 priming of the SDF-1 responsiveness of leukemic cells to an SDF-1 gradient requires further study, as does the role of LL-37 in the metastasis of SDF-1-responsive solid tumors. [23] [24] [25] In our previous studies, we have proposed that short exposure of BM cells to a priming agent (for example, C3a anaphylatoxin) Figure 7 The involvement of LL-37 in the homing and engraftment of HSPCs. Conditioning for transplantation by radio-chemotherapy induces a proteolytic microenvironment in the BM and several proteolytic enzymes are released that decrease the SDF-1 level in the BM. We report here that LL-37 released from BM stroma cells and/or granulocytes present in leucophoresis products enhances/sensitizes the responsiveness of HSPCs to the decreasing SDF-1 gradient. It has been also reported that the complement cascade cleavage fragment anaphylatoxin C3a, 3 UTP 6 and PGE2 7 enhance the responsiveness of HSPCs to an SDF-1 gradient. These observations collectively suggest that the homing responsiveness of HSPCs is positively modulated by several factors related to inflammation or tissue injury.
LL-37 and stem cell homing W Wu et al before transplantation may enhance homing and, as a consequence, accelerate the engraftment of transplanted HSPCs. 3 Here we studied whether priming of murine BM by LL-37 before transplantation shows a similar effect and noticed that murine BM cells exposed for 30 min to LL-37 show HSPC engraftment accelerated by 3-5 days in irradiated animals, which has important clinical implications. As LL-37 is a natural antibacterial peptide that, as we have shown here, does not affect the clonogenecity of normal murine and human hematopoietic progenitors, it could be safely used in the clinic. In fact, in vitro clinical trials with LL-37 as a novel drug for the treatment of bacterial and fungal infection have already been FDA-approved. 9, 26, 27 Thus, priming of HSPCs before transplantation could be a new potential application for this peptide. It would be particularly useful to use LL-37 priming to accelerate the engraftment of UCB HSPCs. It is well known that the number of HSPCs in UCB units is often very low and not optimal for transplantation into an adult recipient. 1 LL-37 in addition to BM stroma cells is also stored in granulocytes and is released from these cells upon activation by C5a. 8 It is well known that the leucophoresis products of mobilized peripheral blood HSPCs are enriched for granulocytes and activated complement cascade cleavage fragments, including C5a. 8 Therefore, HSPCs in mobilized peripheral blood leucophoresis products, in contrast to UCB or BM cells, are exposed to LL-37 released from C5a-activated granulocytes. This may explain why a mobilized product engrafts faster after transplantation than, for example, in UCB or BM cells under steady-state conditions.
Based on these findings, we propose the antimicrobial peptide LL-37 as a potential ex vivo priming factor for HSPCs that may accelerate their engraftment. This strategy would be particularly important for accelerating the engraftment of UCB HSPCs. We also propose a new paradigm in which LL-37 secreted by BM stromal cells together with other priming factors (C3a, UTP and PGE2) may convert a very low level of SDF-1 to a potent chemotactic gradient (Figure 7 ). As the SDF-1 gradient decreases in the BM after conditioning for transplantation owing to the induction of a proteolytic micro-environment, 11 this is an important mechanism promoting HSPCs homing.
